Skeletal metastases from hepatoma: frequency, distribution, and radiographic features

Over the past 6 years, the authors evaluated 300 patients with hepatoma as part of phase 1 and 2 treatment protocol trials. Analysis of the available clinical data and radiographic studies revealed 22 patients (7.3%) with skeletal metastases demonstrated by radiography, computed tomography (CT), and/or nuclear scintigraphy. The plain film appearance of skeletal metastases from hepatoma was osteolytic in all cases. CT scanning best demonstrated the expansile, destructive nature of these metastases, which were often associated with large, bulky soft-tissue masses. Skeletal metastases from hepatomas demonstrated increased radiotracer uptake on standard bone scans and were gallium avid, similar to the hepatoma itself. In addition, they could be targeted therapeutically with I-131 antiferritin immunoglobulin. The most frequent sites of skeletal metastases were the ribs, spine, femur, pelvis, and humerus. An initial symptom in ten patients was skeletal pain corresponding to the osseous metastases. In five patients, pathologic fractures of the proximal femur or humerus developed and required total hip replacement or open-reduction internal fixation. Patients with long-standing cirrhosis or known hepatocellular carcinoma who also have skeletal symptoms should be evaluated for possible osseous metastases.     

叶绿素衍生物在犬膀胱粘膜内代谢的研究

目的：为了了解叶绿素衍生物（ＣＰＤ４）口服后在膀胱粘膜内含量变化的状况，以便为临床应用提供实验依据。方法：１３条实验犬分为３个不同剂量组，应用荧光检测法作服药后不同时段膀胱粘膜ＣＰＤ４含量的测定。结果：ＣＰＤ４用于实验犬的合适剂量是１００ｍｇ／ｋｇ，明显低于此值将显著影响组织的吸收，从而降低光动力作用。在禁食组中，组织内吸收的最高峰值出现在服药后２ｈ，而进食组却推迟出现在服药后６￣１２ｈ。结论：为     

Induction of hepatic microsomal drug metabolizing enzyme system by levamisole in male mice

To examine the effect of levamisole on the hepatic drug metabolizing enzyme system of mice, levamisole at a dose of 20 mg kg-1 day-1 was administered i.p. for 5 days. Compared with the control values, the levamisole treatment significantly increased the amount of cytochrome P450 and cytochrome b5 and the in-vitro activities of aminopyrine N-demethylase, benzphetamine N-demethylase and aniline hydroxylase. In contrast, there was no change in microsomal NADPH-cytochrome c reductase activity in-vitro or in the relative liver weight and microsomal protein content compared with the corresponding values for control mice. Furthermore, in-vivo induction of drug metabolism was demonstrated by decreased pentobarbitone sleeping times after levamisole pretreatment. These results indicate that certain hepatic microsomal mixed function oxidases of mice are induced by levamisole, the drug that is frequently used as an anthelmintic in veterinary medicine and as an immunostimulant drug in human medicine.     

脑内GABA能神经元对红藻氨酸中枢性心血管效应的影响

采用侧脑室微最注射法证明,谷氯酸受体哑型激动剂红藻氨酸(KA)可依剂量性地升高大鼠血压和加快心率。预先给予GABA合成抑制剂氮基脲140 mg/kg ip或GABA拮抗剂印防己毒1 mg/kg iv均可明显增强KA的作用;而GABA转氨酶抑制剂氨氧乙酸25μg/rat icv明显减弱KA的作用。结果表明,脑内GABA能神经元功能受抑,KA的中枢性心血管效应增强。从而推测,脑内GABA能神经元与谷氯酸能神经元之间相互制约,共同参与中枢性调节心血管的活动。     

A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India

The efficacy of a single dose of 45 mg primaquine, as a gametocytocidal agent, was assessed in Mumbai, India, among adults with uncomplicated or severe Plasmodium falciparum malaria. All the patients investigated had been found gametocytaemic, with at least 56 gametocytes/microl blood, within the first 72 h of their illness. Those with uncomplicated malaria, like those with severe malaria, were randomized to receive or not receive primaquine. All the patients were followed up for 29 days post-admission, for gametocytaemia and gametocyte viability (as determined by exflagellation). Among those with uncomplicated malaria, six (27.3%) of the 22 who did not receive primaquine but only one (4.2%) of the 24 who did receive the drug, on day 4, remained gametocytaemic on day 29 (P < 0.05). Similarly, seven (31.8%) of the 22 severe cases who did not receive primaquine but only two (9.5%) of the 21 severe cases who received the drug, on day 8, were found gametocytaemic on day 15 (P < 0.05). While the single, 45-mg dose of primaquine recommended by the World Health Organization was effective in clearing gametocytes from the blood of > 90% of the present cases of malaria, > 4% of the patients with uncomplicated malaria and > 9% of those with the severe disease continued to harbour gametocytes in their peripheral blood 29 and 15 days after taking the primaquine, respectively.